Efficacy and Safety of Zavegepant Nasal Spray for the Acute Treatment of Migraine: Results of a Phase 3 Double-Blind, Randomized, Placebo Controlled Trial

被引:0
|
作者
Mullin, Kathleen [1 ]
Croop, Robert [2 ]
Pavlovic, Jelena M. [3 ]
Mosher, Linda [2 ]
Smith, Timothy R. [4 ]
Madonia, Jennifer [2 ]
Lovegren, Meghan [2 ]
Coric, Vladimir [2 ]
Lipton, Richard B. [3 ]
机构
[1] New England Inst Neurol & Headache, Stamford, CT USA
[2] Biohaven Pharmaceut, New Haven, CT USA
[3] Albert Einstein Coll Med, Bronx, NY USA
[4] StudyMetrix Res, St Louis, MO USA
关键词
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
MTIS22-LBA
引用
收藏
页码:126 / 127
页数:2
相关论文
共 50 条
  • [31] A phase 2/3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rimegepant for the preventive treatment of migraine
    Croop, R.
    Lipton, R. B.
    Kudrow, D.
    Stock, D. A.
    Kamen, L.
    Conway, C. M.
    Stock, E. G.
    Coric, V
    Goadsby, P. J.
    [J]. HEADACHE, 2021, 61 : 98 - 99
  • [32] A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant for the Preventive Treatment of Migraine
    Croop, Robert
    Lipton, Richard
    Thiry, Alexandra
    Kamen, Lisa
    Coric, Vlad
    Goadsby, Peter
    [J]. NEUROLOGY, 2021, 96 (15)
  • [33] Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine - A randomised, double-blind, placebo-controlled study
    Dodick, D
    Brandes, J
    Elkind, A
    Mathew, N
    Rodichok, L
    [J]. CNS DRUGS, 2005, 19 (02) : 125 - 136
  • [34] A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant for the Preventive Treatment of Migraine
    Croop, R.
    Lipton, R. B.
    Kudrow, D.
    Stock, D. A.
    Kamen, L.
    Conway, C. M.
    Stock, E. G.
    Coric, V.
    Goadsby, P. J.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 19 - 19
  • [35] The efficacy and safety of sc Alniditan vs. sc Sumatriptan in the acute treatment of migraine:: a randomized, double-blind, placebo-controlled trial
    Diener, HC
    Tfelt-Hansen, P
    de Beukelaar, F
    Ferrari, MD
    Olesen, J
    Dahlöf, C
    Mathew, N
    [J]. CEPHALALGIA, 2001, 21 (06) : 672 - 679
  • [36] Efficacy of Zavegepant Nasal Spray for the Acute Treatment of Migraine Based on Triptan Treatment Experience: Pooled Results From 2 Randomized, Placebo-Controlled Clinical Trials
    Joshi, Shivang
    Smith, Timothy
    Pavlovic, Jelena
    Mullin, Kathleen
    Croop, Robert
    Madonia, Jennifer
    Mosher, Linda
    Lovegren, Meghan
    Forshaw, Micaela
    Lipton, Richard
    [J]. NEUROLOGY, 2023, 100 (17)
  • [37] Sustained efficacy of STS101 DHE Nasal Powder for the acute treatment of migraine: Results from the Phase 3 double-blind, randomized, placebo-controlled SUMMIT study
    Rapoport, A.
    Spierings, E.
    Albrecht, D.
    [J]. HEADACHE, 2023, 63 : 170 - 170
  • [38] Efficacy of Enalapril in Migraine Prophylaxis: A Randomized, Double-blind, Placebo-controlled Trial
    Sonbolestan, Seyed Ali
    Heshmat, Kiyan
    Javanmard, Shaghayegh Haghjooy
    Saadatnia, Mohammad
    [J]. INTERNATIONAL JOURNAL OF PREVENTIVE MEDICINE, 2013, 4 (01) : 72 - 77
  • [39] Efficacy, Safety, and Tolerability of Rimegepant 75 Mg Orally Dissolving Tablet for the Acute Treatment of Migraine: Results from a Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial, Study 303
    Lipton, R. B.
    Coric, V
    Stock, E. G.
    Stock, D. A.
    Thiry, A. C.
    Conway, C. M.
    Dubowchik, G. M.
    Jensen, C. M.
    Gosden, R.
    Frost, M.
    Gentile, K.
    Morris, B. A.
    Forshaw, M.
    Croop, R.
    [J]. HEADACHE, 2019, 59 : 21 - 22
  • [40] Efficacy, Safety, and Tolerability of Rimegepant 75 mg Orally Dissolving Tablet for the Acute Treatment of Migraine: Results from a Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial, Study 303
    Lipton, Richard B.
    Coric, Vladimir
    Stock, David A.
    Gosden, Ralph
    Forshaw, Micaela
    Croop, Robert
    Conway, Charlie
    [J]. CEPHALALGIA, 2019, 39 : 7 - 8